Patient P-01572
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
87%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 51 SC-12 recommended — Supportive Compound SC-12
- Day 52 Patient declined — Not now
- Day 54 GI-04 recommended — GI Support Protocol GI-04
- Day 55 Patient accepted — Started GI-04 in the companion
- Day 63 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- Treatment adherence-9
- GI instability-6
- Toxicity+6
- Nutritional resilience+4
- Inflammatory activity+3
What helped?
- Supportive Compound SC-12Day 51Declined by patient
- GI Support Protocol GI-04Day 54Result: no meaningful change
LIFE OS recommendation
Dietary Support Protocol NP-02
57%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 71
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 76 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 75 bpm
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 56
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.1 · butyrate capacity 46/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 48 ms
- Sleep
- 5.2 h
- Steps
- 2,888
- Resting HR
- 77 bpm
Daily log: GI score 76, nutritional resilience 32, adherence 39.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01463 | 64% | S14 | NP-02 | no change | 41 |
| P-01897 | 61% | S14 | ME-01 | improved | 43 |
| P-01841 | 60% | S14 | — | — | 48 |
| P-01582 | 56% | S14 | GI-04 | no change | 45 |
| P-01721 | 56% | S14 | — | — | 37 |
| P-01762 | 54% | S14 | NP-02 | no change | 40 |
| P-01612 | 53% | S14 | ME-01 | improved | 51 |
| P-01728 | 53% | S14 | SC-12 | improved | 41 |
| P-01736 | 53% | S03 | ME-01 | improved | 46 |
| P-01830 | 53% | S14 | — | — | 44 |
| P-01772 | 50% | S20 | NP-02 | no change | 50 |
| P-01531 | 49% | S14 | ME-01 | improved | 51 |